Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Aevi Genomic Medicine, Inc. | tv477888_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Aevi Genomic Medicine, Inc. | tv477888_ex31-1.htm |
| 10-Q - 10-Q - Aevi Genomic Medicine, Inc. | tv477888_10q.htm |
Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chapter 63, Title 18 U.S.C. § 1350(a) and (b)), each of the undersigned hereby certifies that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2017 of Aevi Genomic Medicine, Inc. (the “Company”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: November 2, 2017 | /s/ Michael F. Cola |
| Michael F. Cola | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| Date: November 2, 2017 | /s/ Brian D. Piper |
| Brian D. Piper | |
| Chief Financial Officer and Corporate Secretary | |
| (Principal Financial Officer) |